

Supplementary Table 4. Sensitivity analysis of factors associated with TNFi persistence (91-day threshold)

Variable	Univariate analysis				Multivariable analysis 1				Multivariable analysis 2			
	HR	95% CI		<i>p</i> value	HR	95% CI		<i>p</i> value	HR	95% CI		<i>p</i> value
First use of biologics												
Adalimumab	1.05	0.98	1.11	0.181	1.14	1.06	1.23	0.001	1.14	1.06	1.24	0.001
Etanercept	1.01	0.94	1.10	0.757	1.10	1.01	1.20	0.032	1.10	1.01	1.21	0.028
Infliximab	0.75	0.69	0.82	< 0.001	0.83	0.76	0.91	< 0.001	0.83	0.75	0.91	< 0.001
Golimumab	1.00			< 0.001	1.00			< 0.001	1.00			< 0.001
Sex												
Male	1.00											
Female	1.01	0.95	1.08	0.675								
Age group (yr)												
20–59	1.00				1.00				1.00			
60–84	1.08	0.99	1.18	0.083	1.04	0.95	1.14	0.410	1.04	0.95	1.14	0.370
Type of medical institution												
Tertiary hospital	1.00			< 0.001	1.00			< 0.001				< 0.001
General hospital	1.22	1.15	1.29	< 0.001	1.21	1.14	1.28	< 0.001	1.20	1.13	1.26	< 0.001
Hospital	1.27	1.15	1.39	< 0.001	1.18	1.06	1.32	0.002	1.22	1.10	1.35	0.000
Clinic	1.33	1.10	1.61	0.004	1.28	1.05	1.56	0.015	1.22	1.00	1.48	0.053
Clinical specialty												
Internal medicine	1.00			< 0.001	1.00			< 0.001				
Orthopedics	1.07	0.98	1.16	0.123	1.05	0.95	1.17	0.331				
Neurosurgery	1.55	1.34	1.80	< 0.001	1.49	1.26	1.78	< 0.001				
Others	2.45	1.76	3.42	< 0.001	2.53	1.81	3.54	< 0.001				
Department												
Internal medicine	1.00								1.00			
Non-internal medicine	1.18	1.09	1.27	< 0.001					1.15	1.04	1.27	0.005
Comorbidities (1 year prior to biologics initiation)												
Diabetes mellitus	1.01	0.94	1.10	0.760								
Dyslipidemia	1.08	1.03	1.14	0.003	1.06	1.01	1.12	0.033	1.07	1.01	1.12	0.018
Hypertension	1.01	0.95	1.08	0.705								
Ischemic heart disease	0.96	0.85	1.10	0.571								
Stroke	0.92	0.74	1.13	0.426								
Asthma	0.93	0.85	1.02	0.138								
COPD	0.96	0.72	1.29	0.784								
Charlson comorbidity index												
0	1.00			0.331								
1	1.00	0.94	1.07	0.930								
2+	1.04	0.98	1.11	0.175								

TNFi, tumor necrosis factor inhibitor; HR, hazard ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease.